Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

MK-7262 · HRS-5346

Oligonucleotide (Antisense oligonucleotide) · developed by Merck &

Phase 2 Most advanced trial

MRK Developer

1 Registered trials

What is MK-7262?

MK-7262 (HRS-5346) is an antisense oligonucleotide targeting lipoprotein(a) (Lp(a)) mRNA. It is being studied to lower Lp(a) levels in patients with elevated lipoprotein(a).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: HRS-5346
Drug type: Oligonucleotide (Antisense oligonucleotide)
Therapy area: Cardiovascular
Developer: Merck & Co. (MRK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07614984	Phase 2	Lipoprotein(a)	Recruiting	MRK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lipoprotein(a)

More from Merck &

BCG Live FDA approved Belzutifan FDA approved Berahyaluronidase Alfa FDA approved Berahyaluronidase Alfa and Pembrolizumab FDA approved Enlicitide FDA approved Ensifentrine FDA approved Letermovir FDA approved Pembrolizumab FDA approved Probenecid FDA approved Alimatravir Phase 2 Bomedemstat Phase 2/3 Calderasib Phase 3

Follow MRK, the company behind MK-7262

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z